SZN-413

N/A

Report date: 2022/10/20 15:04:39

Base Information

Drug NameSZN-413
Drug Alias NameSZN-413
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionFrizzled-4 agonistsWnt signalling pathway stimulantsAnti-LRP5
TargetsFrizzled-4Low-density lipoprotein receptor-related protein 5
Therapy Area/IndicationsDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSurrozen Inc
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgSurrozen Inc
Inactive CompaniesN/A
Active IndicationsDiabetic Retinopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A